Immune regulation by dimethylfumarate (DMF) in patients with relapsing Remitting Multiple Sclerosis.
Phase 4
Recruiting
- Conditions
- Multiple SclerosisMS10012303
- Registration Number
- NL-OMON41017
- Lead Sponsor
- Orbis Medisch Centrum
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 20
Inclusion Criteria
Relapsing Remitting Multiple Sclerose according to 2010 revised McDonald criteria
Age > 18 years
Disease duration < 5 years
Exclusion Criteria
Relapse < 6 weeks prior to inclusion
Use of glucocorticosteriods < 6 weeks prior to inclusion
Use of disease modifying therapies in the past.
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method